Kupert et al. BMC Cancer 2011, 11:513 http://www.biomedcentral.com/1471-2407/11/513 association with serum levels of sPLA2IIa: results from the UDACS study. Human Mol Genet 2006, 15(2):355-361. 35. Yamaguchi O, Sugimura K, Ishizuka K, Suzuki K, Hasegawa K, Ohtsuka K, Honma T, Asakura H: Correlation between serum phospholipase A(2) IIA levels and histological activity in patients with ulcerative colitis. Int J Colorectal Dis 2002, 17(5):311-316. 36. Serdar MA, Oguz O, Olgun A, Seckin B, Ilgan S, Hasimi A, Salih M, Peker F, Kutluay T: Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together. Ann Clin Lab Sci 2002, 32(1):22-30. 37. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. The New England J Med 1991, 324(17):1156-1161. 38. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE: Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. European urology 2005, 48(3):386-399, discussion 398-389. 39. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y: Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000, 55(6):791-795. 40. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. The New England J Med 2004, 350(22):2239-2246. 41. Gilbert SM, Cavallo CB, Kahane H, Lowe FC: Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005, 65(3):549-553. 42. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S, Montalto G: Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003, 23(2C):1747-1753. 43. el-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS, Elsayed AA: Enhanced detection of hepatocellular carcinoma. Cancer Control 2005, 12(4):248-253. 44. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW: Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004, 20(2):53-70. 45. Buchen L: Cancer: Missing the mark. Nature 2011, 471(7339):428-432. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/513/prepub doi:10.1186/1471-2407-11-513 Cite this article as: Kupert et al.: Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer 2011 11:513. Page 10 of 10 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit